<DOC>
	<DOCNO>NCT00838396</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety arbaclofen placarbil ( XP19986 ) compare placebo patient gastroesophageal reflux disease .</brief_summary>
	<brief_title>A Study Evaluate Efficacy Safety Controlled Release Arbaclofen Placarbil ( XP19986 ) Patients With Gastroesophageal Reflux Disease</brief_title>
	<detailed_description />
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<mesh_term>Arbaclofen placarbil</mesh_term>
	<mesh_term>Baclofen</mesh_term>
	<criteria>1 . History GERD symptom ( e.g . heartburn episode ) least 3 time per week 2 . Discontinuation drug use treat GERD ( PPIs , H2blockers ) and/or drug know cause GERD symptom ( e.g . nonsteroidal antiinflammatory drug [ NSAIDs ] ) 7 day prior baseline ( Visit 2 ) ; 3 . Had great equal 20 postprandial reflux episodes/2 hour record use impedance/pH monitoring Screening/Baseline period ( Visit 2 ) 1 . History gastrointestinal disorder GERD may significantly affect assessment reflux episodes GERD symptom ( e.g . Barrett 's Esophagus , active gastric duodenal ulcer disease , achalasia , scleroderma , etc. ) . 2 . Medical condition could affect assessment reflux episode GERD symptom ( e.g . history nausea and/or vomiting , neurologic/psychiatric disorder , cardiac disease [ e.g . angina ] , lung disease [ e.g . asthma , cough ] , etc . )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>